EVENTS:   Best Equity Short Ideas Conference Call 12 - Zach Shannon/Corto Capital Advisors & Craig Huber/Huber Research Partners & Thomas Beevers /Forensic Alpha & Ed Steele/Iron Blue Financials & Bill Campbell/Paragon Intel - 12 Nov 25   Will AI Deflate the World? Macro Lessons from Three Industrial Revolutions and China - Manoj Pradhan/Talking Heads Macro - 13 Nov 25     ROADSHOWS: Forest Products Sector Equity and Commodity Research With Expertise in Distressed Debt - Kevin Mason /ERA Research   •   London   12 - 14 Nov 25       Buyside to Buyside Forum and Expert Calls across TMT, Consumer, Healthcare and Fintech - Andrew Peters /Revelare Partners   •   London   17 - 19 Nov 25       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   17 - 19 Nov 25      

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

The Psychedelic Revolution

Healthcare

Inferential Focus

The potential of using psychedelics for therapeutic benefit has taken several steps forward recently. The FDA is getting closer to issuing specific guidance and guidelines for the use of psychedelic drugs to treat mental illnesses - notably for depression and PTSD - as well as for addictions and for use in clinical trials. Psychedelics are gaining cultural awareness and acceptance, with two US states (Oregon and Colorado) legalising controlled uses. Investors are taking notice. By last year, more than 50 psychedelics companies, including Compass Pathways and ATAI Life Sciences, had gone public at a combined valuation of over $2bn.

Edition: 167

- 18 August, 2023